FDA.reportPublic FDA data

PYtest ( 14 C-Urea Capsules)

Manufacturer
Avent, Inc.
Effective date
2022-06-07
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
7
Source
legacy-cache
Hydrated at
2026-08-01 21:59:53

Label at a glance#

ProductPYtest
Active ingredientUrea C-14
Label structure18 sections

Indications and uses

PYtest ( 14 C-Urea breath test) is indicated for use in the detection of gastric urease as an aid in the diagnosis of H. pylori infection in the human stomach. The test utilizes a liquid scintillation counter for the measurement of 14 CO 2 in breath samples.

Dosage and administration

FOR ANALYSIS AT TEST SITE BREATH SAMPLE COLLECTED INTO BALLOON (RECOMMENDED METHOD; SEE FIGURE 2 ) Breath test report form Stopwatch/Timer capable of timing an interval up to 10 minutes Marking pen 1 – 20 ml scintillation vial Breath transfer pump Pipette (10 ml) for measuring fluids Collection fluid (2.5 ml/vial) Scintillation fluid (10 ml/vial) 1 – Mylar collection balloon 1 – Straw 2 – Needles 2 – 30 ml medicin...

Label contents#

Full prescribing information#

Description

DESCRIPTION SECTION

PYtest1 (14C-urea capsules) is intended for use in the detection of gastric urease as an aid in the diagnosis of Helicobacter pylori (H. pylori) infection in the human stomach. The test utilizes a liquid scintillation counter for the measurement of 14CO2 in breath samples. The capsules are to be used when analysis is planned at the site where the sample is taken.

PYtest1 capsule is a gelatin capsule for oral administration containing 1 µCi of 14C labeled urea. The urea is adsorbed on sugar spheres and colored yellow with fluorescein.

1 Registered Trademark or Trademark of Kimberly-Clark Worldwide, Inc.

Data on 14C-urea

SPL UNCLASSIFIED SECTION

Structural Formula (14C-urea): NH2 14CONH2

Radiation emission: beta-emission, 49 keVmean, 156 keVmax, no other emissions

External emission: No external radiation hazard. Low-energy beta emissions only.

Maximum range of 0.3 mm in water.

Radiological Half-life: 5730 years

Maximum effective dose equivalent (EDE) : 0.3 mrem/µCi

Clinical Pharmacology

CLINICAL PHARMACOLOGY SECTION

The urease enzyme is not present in mammalian cells, so the presence of urease in the stomach is evidence that bacteria are present. The presence of urease is not specific for H. pylori, but other bacteria are not usually found in the stomach. The principle of the breath test is shown in Figure 1.

Figure 1: Principle of Breath Test

Figure 1: Principle of Breath Test
Figure 1: Principle of Breath Test

To detect H. pylori, urea labeled with 14C is swallowed by the patient. If gastric urease from H. pylori is present, urea is split to form CO2 and NH3 at the interface between the gastric epithelium and lumen and 14CO2 is absorbed into the blood and exhaled in the breath.

Following ingestion of the capsule by a patient with H. pylori, 14CO2 excretion in the breath peaks between 10 and 15 minutes and declines thereafter with a biological half-life of about 15 minutes. 14C-urea that is not hydrolyzed by H. pylori is excreted in the urine with a half-life of approximately 12 hours. About 10% of the 14C remains in the body at 72 hours and is gradually excreted with a biological half-life of 40 days.

Clinical Studies

CLINICAL STUDIES SECTION

Two studies were performed. In both studies, patients with gastrointestinal symptoms underwent the breath test and an endoscopy. During the endoscopy, biopsy samples were taken from the antral gastric mucosa for histological analysis (2 samples, Giemsa stain) and rapid urease test (1 sample, CLOtest1). Breath samples were mailed to the TRI-MED lab where they were read in a liquid scintillation counter.

Results were reported as disintegrations per minute (DPM). Analysis for accuracy used the ten minute breath sample. A breath sample DPM <50 was defined as a negative result. DPM ≥ 200 was defined as a positive result. DPM in the range of 50–199 was classified as indeterminate.

STUDY 1

SPL UNCLASSIFIED SECTION

Of 186 patients who had histopathology and CLOtest1 (80 men, 106 women), 53 were infected with H. pylori as determined by agreement between histology and CLOtest1. The study results are summarized below:

Table 1: Study #1 (n = 186, Indeterminate results included)
Histology and CLOtest1
H. pyloriPositiveNegativeTotal
Notes: PYtest1 at 10 min. was compared to the gold standard of biopsy results in which histology and CLOtest1 concurred. Patients who did not have both biopsy tests performed, or in whom the tests differed, were excluded from analysis. There was no statistical difference in test accuracy based on gender of patient.
ppv = positive predictive value (true positive divided by total PYtest1 positive)
npv = negative predictive value (true negative divided by total PYtest1 negative)
PYtest1 Positive51859ppv.86%
(DPMIndeterminate189
10 min.)Negative1117118npv.99%
Total53133186
sensitivityspecificity
96%88%

STUDY 2

SPL UNCLASSIFIED SECTION

Breath tests were performed on 436 outpatients attending gastroenterology practices at sites in the United States. Seventy-six patients (40 men, 36 women) who had histology and CLOtest1 were evaluated. The results are summarized below:

Table 2: Study #2 (n = 76, Indeterminate results included)
Histology and CLOtest1
H. pyloriPositiveNegativeTotal
Notes: PYtest at 10 min. was compared to the gold standard of biopsy results in which histology and CLOtest concurred. Patients who did not have both biopsy tests performed, or in whom the tests differed, were excluded from analysis. There was no statistical difference in test accuracy based on gender of patient.
ppv = positive predictive value (true positive divided by total PYtest1 positive)
npv = negative predictive value (true negative divided by total PYtest1 negative)
PYtest1 Positive22022ppv.100%
(DPMIndeterminate426
10 min.)Negative14748npv.98%
Total274976
sensitivityspecificity
82%96%

Indications and Usage

INDICATIONS & USAGE SECTION

PYtest1 (14C-Urea breath test) is indicated for use in the detection of gastric urease as an aid in the diagnosis of H. pylori infection in the human stomach. The test utilizes a liquid scintillation counter for the measurement of 14CO2 in breath samples.

Contraindications

CONTRAINDICATIONS SECTION

None

Warnings

WARNINGS SECTION

None

Precautions

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

After the patient ingests the 14C-urea capsule, the sample collected for test purposes is for in vitro diagnostic use only.

A false positive test could occur in patients who have achlorhydria. Very rarely, a false positive test may occur due to urease associated with Helicobacters other than H. pylori (i.e. Helicobacter heilmanni).

Limitations of the Test

SPL UNCLASSIFIED SECTION

  • The test has been evaluated in outpatients before elective endoscopy.
  • Test results should be evaluated with clinical signs and patient history when diagnosing H. pylori infection.
  • The performance characteristics of the test have not been established for monitoring the efficacy of antimicrobial therapies for the treatment of H. pylori infection.
  • A negative result does not completely rule out the possibility of H. pylori infection. If clinical signs and patient history suggest H. pylori infection, repeat the PYtest1 or use an alternative diagnostic method.
Radioactivity

SPL UNCLASSIFIED SECTION

Persons concerned about very low doses of radioactivity may postpone the test or may decide to use an alternative means of diagnosis. The test produces radiation exposure equal to 24 hours of normal background. In animal experiments, such low doses of radiation do not carry measurable risk.

Preclinical studies were not conducted on 14C-urea. The estimated dose equivalent received from a single administration of PYtest1 (1 µCi 14C) is about 0.3 mrem.

Information for Patients

INFORMATION FOR PATIENTS SECTION

It is necessary for the patient to fast for 6 hours before the test. The patient should also be off antibiotics and bismuth for 1 month, and proton pump inhibitors and sucralfate for 2 weeks prior to the test. Instruct the patient not to handle the capsule directly as this may interfere with the test result. The capsule should be swallowed intact. Do not chew the capsule.

Carcinogenesis, mutagenesis, impairment of fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No studies have been conducted with 14C-urea to evaluate its potential for carcinogenicity, impairment of fertility, or mutagenicity.

Drug Interactions

DRUG INTERACTIONS SECTION

Antibiotics, proton pump inhibitors, sucralfate, and bismuth preparations are known to suppress H. pylori. Ingestion of antibiotics or bismuth within 4 weeks and proton pump inhibitors or sucralfate within 2 weeks prior to performing the test may give false negative results.

Pregnancy

PREGNANCY SECTION

Pregnancy category C

TERATOGENIC EFFECTS SECTION

Animal reproduction studies have not been conducted with PYtest1 (14C-urea). It is also not known whether PYtest1 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. PYtest1 should be given to a pregnant woman only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when PYtest1 is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Clinical studies in children have not been conducted. However, PYtest1 is expected to work the same in children as in adults. While the dose (1 capsule) does not need to be adjusted, the child must be able to swallow the intact capsule and blow into a straw.

Adverse Reactions

ADVERSE REACTIONS SECTION

No adverse reactions were reported in clinical trials.

Overdosage

OVERDOSAGE SECTION

Risk from radiation is negligible even with a 1000 capsule overdose (0.3 rem). If overdose occurs, the patient may drink one glass of water (150 ml) every hour to hasten excretion of the isotope. Maximum excretion of urea is achieved at a urine output of ≥ 2.0 ml/min.

Dosage and Administration

DOSAGE & ADMINISTRATION SECTION

Materials Needed but not Provided

SPL UNCLASSIFIED SECTION

FOR ANALYSIS AT TEST SITE
BREATH SAMPLE COLLECTED INTO BALLOON
(RECOMMENDED METHOD; SEE FIGURE 2)

  • Breath test report form
  • Stopwatch/Timer capable of timing an interval up to 10 minutes
  • Marking pen
  • 1 – 20 ml scintillation vial
  • Breath transfer pump
  • Pipette (10 ml) for measuring fluids
  • Collection fluid (2.5 ml/vial)
  • Scintillation fluid (10 ml/vial)
  • 1 – Mylar collection balloon
  • 1 – Straw
  • 2 – Needles
  • 2 – 30 ml medicine cups
  • Water (40 ml)
  • Any gas pump that is airtight and has a flow rate between .5 and 1 liter per minute may be used.

Figure 2: Other Components

Figure 2: Other Components
Figure 2: Other Components

SPL UNCLASSIFIED SECTION

FOR ANALYSIS ON SITE
BREATH SAMPLE COLLECTED INTO VIAL

CAUTION: Kimberly-Clark does not endorse breath sample collection by this method because patients might come into direct contact with the hyamine.

  • Breath test report form
  • Stopwatch/Timer capable of timing an interval up to 10 minutes
  • Safety trap (Figure 3)
  • 1 – Straw
  • 1 – 20 ml scintillation vial
  • Marking pen
  • Pipette (10 ml) for measuring fluids
  • Collection fluid (2.5 ml/vial)
  • Scintillation fluid (10 ml/vial)

Figure 3: Typical Safety Trap

Figure 3: Typical Safety TrapFigure 3: Typical Safety Trap

Dosage

DOSAGE FORMS & STRENGTHS SECTION

One PYtest1 capsule.

Procedural Notes

SPL UNCLASSIFIED SECTION

  • Inform the patient to fast for 6 hours prior to the test.
  • The patient should be off antibiotics and bismuth for 1 month, and proton pump inhibitors and sucralfate for 2 weeks prior to the test.
  • Have patient sitting at rest while doing the test.
  • The capsule should not be handled directly as this may interfere with the test result.
  • To avoid contamination by bacteria in the mouth, the capsule should be swallowed intact. Do not chew capsule.

Step by Step Procedure for Balloon

SPL UNCLASSIFIED SECTION

Breath Sample Collection by Balloon
Before the test
  1. Label balloon and fill in breath test report form.
  2. Check that all materials are present.
Minus
1 minute
  1. Open the package containing the 14C-urea capsule and 1 minute tip the capsule into the empty 30 ml cup. Do not handle the capsule directly.
  2. Hand the cup to the patient.
  3. Fill the second cup with 20 ml lukewarm water.
0 minute
  1. Ask the patient to tip the capsule directly into his/her mouth, then swallow it with the 20 ml of lukewarm water.
  2. Start the stopwatch when the patient swallows the capsule.
  3. Discard waste (e.g., capsule packaging, used straws) according to your facility's regulations.
3 minutesAsk the patient to drink another 20 ml of lukewarm water (in case the capsule may have lodged in the esophagus and not yet reached the gastric mucosa).
10 minutes
  1. Push a drinking straw into the neck of the balloon.
  2. Ask the patient to hold his/her breath for 5–10 seconds, then blow up a balloon with a slow breath through the straw, filling the balloon completely.
  3. Tie the neck of the balloon into a tight knot.
  4. Check that the balloon label and the breath test report form are completed correctly.
After
sample
collection		See test analysis procedure.
Breath Sample Collection by Vial
CAUTION: Kimberly-Clark does not endorse the collection of breath samples by this method for patient safety reasons.
Before the
test
  1. Label vial and fill in breath test report form. Vial label should include the patient's name, date of sample collection and time sample is taken.
  2. Check that the vial contains 2.5 ml of collection fluid (1.5 ml methanol, 1.0 ml 1 molar hyamine, two drops thymolphthalein pH indicator).
  3. Check that all materials are present.
Minus
2 minutes		Attach a straw to the safety trap (Figure 3).
Minus
1 minute
  1. Open the package containing the 14C-urea capsule and tip the capsule into the 30 ml cup. Do not handle the capsule directly.
  2. Hand the cup to the patient.
  3. Fill the second cup with 20 ml lukewarm water.
0 minute
  1. Ask the patient to tip the capsule directly into his/her mouth, then swallow it with the 20 ml of lukewarm water.
  2. Start the stopwatch when the patient swallows the capsule.
  3. Discard waste (e.g., capsule packaging, used straw) according to your facility's regulations.
3 minutesAsk the patient to drink another 20 ml of lukewarm water (in case the capsule may have lodged in the esophagus and not yet reached the gastric mucosa).
10 minutesAsk the patient to hold his/her breath for 5–10 seconds, then blow bubbles into the collection fluid via the safety trap. The patient should blow bubbles until the fluid turns clear. Put lid on vial.
After
sample
collection		See test analysis procedure.

Test Analysis Procedure

SPL UNCLASSIFIED SECTION

General Information

SPL UNCLASSIFIED SECTION

  • The collection fluid contains hyamine, methanol and a pH indicator. Hyamine is a corrosive caustic alkali. If you are using the vial method and collecting breath directly into the collection fluid you must supervise the patient and ensure that a safety trap is used.
  • The amount of hyamine (1 ml of 1/m) and methanol (2.5 ml) in one collection vial is not sufficient to cause serious poisoning. Local irritation to skin or mucous membranes is likely when the solution is blue. After collecting CO2 the collection fluid turns clear. At this point it is less dangerous because the pH is near neutral.
  • If the collection fluid splashes onto the skin or eyes, wash immediately with water. If the collection fluid is accidentally ingested, wash the mouth with water and have the patient drink 250 ml of water immediately. Consult your poison information center for further facts on hyamine.
  • Scintillation fluid comes in many formulations. It is usually a mixture of toluene and various cyclic hydrocarbons. It is flammable. Biodegradable formulations do exist. Consult your supplier if you have questions.

BALLOON READ ON-SITE:

  1. Add 2.5 ml collection fluid to each vial.
  2. Label the scintillation vial lid to match the label on the balloon.
  3. Attach a needle to the inlet and outlet tubes on the pump.
  4. Turn on pump. Allow to run for about 15 seconds.
  5. Put needle from the rigid outlet tube in a vial until it makes bubbles in the collection fluid.
  6. Pierce the label of a filled balloon with the other needle and hold it in a stable position. (Do not pierce the balloon anywhere else or it may tear. Do not squeeze the balloon.)
  7. After 2–3 minutes the collection fluid should turn colorless.
  8. After the collection fluid is colorless, remove the needles from the balloon and collection fluid and discard according to your facility protocol.
  9. Change needles between patients.
  10. Turn off pump after last patient sample is transferred.
  11. Double check that the label on the vial lid matches the label on the balloon.
  12. Add 10 ml scintillation fluid to each vial and mix fluid.
  13. Count the sample in liquid scintillation counter for 5 minutes or as directed by the liquid scintillation counter manufacturer. (Note that values of 50–300 DPM can occur immediately after the addition of the scintillation fluid due to chemiluminescence. Chemiluminescence decays rapidly over an hour or two and will reveal itself by falling counts. Read the sample repeatedly until values 10 minutes apart are similar. If DPM is still 50–300, you should allow the sample to settle for 12–24 hours before re-testing.)
  14. Include a standard and a blank control vial in each run.

VIALS READ ON-SITE

See steps 12–14 under "Balloon read on-site."

Quality Control

SPL UNCLASSIFIED SECTION

A minimum of 1 mmol of CO2 is required to perform analysis of a breath sample. The amount of breath required to provide 1 mmol of CO2 varies depending on the amount of CO2 the patient is producing. Since a full balloon typically contains at least 1 mmol of CO2, the balloon should be completely filled.

Results

SPL UNCLASSIFIED SECTION

Interpretation of results (10 minute sample)
     < 50 DPMNegative for H. pylori
     50–199 DPMIndeterminate for H. pylori
     ≥ 200 DPMPositive for H. pylori

The indeterminate result should be evaluated by repeating the PYtest1 or using an alternative diagnostic method. If repeat breath testing is undertaken, careful history to exclude confounding factors should be obtained. If confounding factors are identified, wait an appropriate time (refer to table 3) before repeating the PYtest1.

The cutoff point of 50 DPM was determined to be the mean +3SD of results obtained in patients who did not have H. pylori.

DPM = Disintegrations per minute

Table 3: Factors which might cause sub-optimal breath test results
FactorResultComment
Recent antibiotic or bismuth
(Pepto-Bismol, etc.)		false
neg.		Relapse of partially treated Hp may take 1–4 weeks.
Omeprazole (or other proton pump inhibitors)false
neg.		These agents suppress Hp in 40% of patients. Discontinuefor at least 2 weeks before performing the PYtest1.
Resective gastric surgeryfalse
neg.		Isotope may empty rapidly from the stomach.
Resective gastric surgeryfalse
pos.		Patient may be achlorhydric and have bacterial overgrowth (non-Hp urease).
Food in stomach (also bezoar, gastroparesis)unknownIsotope may not come into contact with gastric mucosa Patient may be achlorhydric and/or have bacterial overgrowth (non-Hp urease).

Expected Values

SPL UNCLASSIFIED SECTION

As shown in Figure 4 approximately 30% of patients tested will be positive for H. pylori.

Figure 4: Histogram showing DPM distribution for the PYtest1.

Figure 4: Histogram showing DPM distribution for the PYtest*.Figure 4: Histogram showing DPM distribution for the PYtest*.

*Note: DPM groupings were calculated on a logarithmic scale. Empty DPM groupings were not included. Chart includes all patients from Studies 1 and 2. Frequency of DPM group includes samples with DPM < Group Name.

  • DPM = Disintegrations per minute
  • Gold Standard = Agreement between histology and CLOtest1

If the capsule is damaged or appears abnormal in any way, it may give inaccurate results.

HOW SUPPLIED

HOW SUPPLIED SECTION

PYtest1 Capsules, clear gelatin capsules each containing 1 μCi of 14C-urea in unit dose packages of 1, 10 and 100.

PYtest1 Kit (14C-urea breath test) is also supplied as a kit containing a PYtest1 Capsule and breath collection equipment.

STORAGE AND HANDLING SECTION

The PYtest1 Capsule has a shelf life of two years. The expiration date is printed on the capsule label.

PYtest1 Capsules and Kit should be stored at 15–30 °C (59–86 °F) in an area designated by each individual institution's regulations.

SPL UNCLASSIFIED SECTION

Rx Only (USA)

U.S. Patent Nos. 4,748,113; 4,830,010

SPL UNCLASSIFIED SECTION

Kimberly-ClarkDistributed in the U.S. by Kimberly-Clark Global Sales, LLC, Roswell, GA 30076 USA
In USA, please call 1-800-KCHELPS • www.kchealthcare.com
Kimberly-Clark, Roswell, GA 30076 USA
Kimberly-Clark N.V., Belgicastraat 13, 1930 Zaventem, Belgium
Sponsored in Australia by Kimberly-Clark Australia Pty Limited; 52 Alfred Street
Milsons Point, NSW 2061 • 1-800-101-021
©2003 KCWW. All rights reserved.
14-63-133-0-00/70080916

PRINCIPAL DISPLAY PANEL - 10 Capsule Package Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

AVANOS*

PYtest*
14C-UREA BREATH TEST CAPSULES
FOR THE DETECTION OF HELICOBACTER PYLORI

Contents – 10 PYtest* Capsules each containing 1 µCi 14C-Urea

For dosage information, please see package insert

14C-Urea (5730 years1/2, 156 keV[max.] β-emission)

NDC 42536-6044-2

For In Vitro
Diagnostic Use

Rx Only

Store at
15°–30°C
(59°–86°F)

REF
60442

PRINCIPAL DISPLAY PANEL - 10 Capsule Package Label
PRINCIPAL DISPLAY PANEL - 10 Capsule Package Label

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
42536-6044-12022-06-07C16284748780-1d6a99b39-6cd0-a426-e053-dadaa90af4c2PYtest ( 14 C-Urea Capsules)
42536-6044-22022-06-07C16284748780-1d6a99b39-6cd0-a426-e053-dadaa90af4c2PYtest ( 14 C-Urea Capsules)
42536-6044-32022-06-07C16284748780-1d6a99b39-6cd0-a426-e053-dadaa90af4c2PYtest ( 14 C-Urea Capsules)
42536-6044-12022-01-28C16284748780-1d6a99b39-6cd0-a426-e053-dadaa90af4c2PYtest ( 14 C-Urea Capsules)
42536-6044-22022-01-28C16284748780-1d6a99b39-6cd0-a426-e053-dadaa90af4c2PYtest ( 14 C-Urea Capsules)
42536-6044-32022-01-28C16284748780-1d6a99b39-6cd0-a426-e053-dadaa90af4c2PYtest ( 14 C-Urea Capsules)

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
Urea, C-14ACTIVE INGREDIENTWBZ6M63TEE1
Urea, C-14ACTIVE MOIETYWBZ6M63TEE1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 3 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
42536-604442536-6044-1, 42536-6044-2, 42536-6044-3

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 1 matching rows.

Name, UNII, Kind table
NameUNIIKind
Urea C-14WBZ6M63TEEACTIB

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N020617-001PYTESTUREA, C-141uCiCAPSULE / ORALRLD1997-05-09
N020617-002PYTEST KITUREA, C-141uCi **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CAPSULE / ORALRLD1997-05-09

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 88 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09N020617-001PYTEST1uCiCAPSULE / ORALRLD1997-05-09c2088c7a36db…
2026-10-15 13:18:302026-09N020617-002PYTEST KIT1uCi **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CAPSULE / ORALRLD1997-05-09c2088c7a36db…
2026-09-14 22:38:342026-08N020617-001PYTEST1uCiCAPSULE / ORALRLD1997-05-0984e616aacf4f…
2026-09-14 22:38:342026-08N020617-002PYTEST KIT1uCi **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CAPSULE / ORALRLD1997-05-0984e616aacf4f…
2026-08-18 06:07:402026-07N020617-001PYTEST1uCiCAPSULE / ORALRLD1997-05-09caaa826d4ba7…
2026-08-18 06:07:402026-07N020617-002PYTEST KIT1uCi **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CAPSULE / ORALRLD1997-05-09caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N020617-001PYTEST1uCiCAPSULE / ORALRLD1997-05-09011fe1cb6892…
2026-02-19 14:30 UTC2026-02N020617-002PYTEST KIT1uCi **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CAPSULE / ORALRLD1997-05-09011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020617-001PYTEST1uCiCAPSULE / ORALRLD1997-05-0931067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020617-002PYTEST KIT1uCi **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CAPSULE / ORALRLD1997-05-0931067a03dcf5…
2025-08-23 18:47 UTC2025-08N020617-001PYTEST1uCiCAPSULE / ORALRLD1997-05-096a471c1ec25d…
2025-08-23 18:47 UTC2025-08N020617-002PYTEST KIT1uCi **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CAPSULE / ORALRLD1997-05-096a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N020617-001PYTEST1uCiCAPSULE / ORALRLD1997-05-09fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N020617-002PYTEST KIT1uCi **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CAPSULE / ORALRLD1997-05-09fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N020617-001PYTEST1uCiCAPSULE / ORALRLD1997-05-09b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N020617-002PYTEST KIT1uCi **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CAPSULE / ORALRLD1997-05-09b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N020617-001PYTEST1uCiCAPSULE / ORALRLD1997-05-0903ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N020617-002PYTEST KIT1uCi **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CAPSULE / ORALRLD1997-05-0903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N020617-001PYTEST1uCiCAPSULE / ORALRLD1997-05-092680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N020617-002PYTEST KIT1uCi **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CAPSULE / ORALRLD1997-05-092680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N020617-001PYTEST1uCiCAPSULE / ORALRLD, RS1997-05-095bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N020617-002PYTEST KIT1uCi **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CAPSULE / ORALRLD1997-05-095bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N020617-001PYTEST1uCiCAPSULE / ORALRLD1997-05-09d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N020617-002PYTEST KIT1uCi **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CAPSULE / ORALRLD1997-05-09d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N020617-001PYTEST1uCiCAPSULE / ORALRLD1997-05-09d06236e962d9…
2024-10-29 15:01 UTC2024-10N020617-002PYTEST KIT1uCi **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**CAPSULE / ORALRLD1997-05-09d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N020617-001PYTEST1uCiCAPSULE / ORALRLD, RS1997-05-0979d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N020617-002PYTEST KIT1uCiCAPSULE / ORALRLD1997-05-0979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N020617-001PYTEST1uCiCAPSULE / ORALRLD, RS1997-05-09301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N020617-002PYTEST KIT1uCiCAPSULE / ORALRLD1997-05-09301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N020617-001PYTEST1uCiCAPSULE / ORALRLD, RS1997-05-091e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N020617-002PYTEST KIT1uCiCAPSULE / ORALRLD1997-05-091e350fbaab3a…
2024-05-31 18:47 UTC2024-05N020617-001PYTEST1uCiCAPSULE / ORALRLD, RS1997-05-098072bd15b7f6…
2024-05-31 18:47 UTC2024-05N020617-002PYTEST KIT1uCiCAPSULE / ORALRLD1997-05-098072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N020617-001PYTEST1uCiCAPSULE / ORALRLD, RS1997-05-095c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N020617-002PYTEST KIT1uCiCAPSULE / ORALRLD, RS1997-05-095c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N020617-001PYTEST1uCiCAPSULE / ORALRLD, RS1997-05-095d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N020617-002PYTEST KIT1uCiCAPSULE / ORALRLD, RS1997-05-095d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N020617-001PYTEST1uCiCAPSULE / ORALRLD, RS1997-05-094b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N020617-002PYTEST KIT1uCiCAPSULE / ORALRLD, RS1997-05-094b0b4de00fa7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
98311ae8-b8a0-4d38-897b-b74b91817cdb13148b04-9295-41bb-bd8b-76dbd4ce7c002024-09-16Warnings, Adverse reactionsExact identifier
spl set id: 13148b04-9295-41bb-bd8b-76dbd4ce7c00

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.